by By Jeff Hansen, University of Alabama at Birmingham Systematic mapping of m1A sites in small RNA space. a) Chemical structure of m1A (N1-methyladenosine). b) Overall m1A mapping strategy for small RNAs by combining m1A RIP and m1A-induced mismatch analysis. Synthetic m1A RNA is included as a positive control. c) TGIRT identified as the optimal...
Tag: <span>Bladder Cancer</span>
New urine test for bladder cancer could reduce need for invasive and time-consuming diagnostic procedures
by University of Birmingham Mutation frequencies across incident bladder cancer stages and grades. Data are shown for the six genes most frequently mutated (overall) in grade 1 pTa (n = 23), grade 2 pTa (n = 42), grade 3 pTa (n = 15), grade 3 pT1 (n = 24), and grade 2 pTa (n =...
Therapeutically effective drugs for bladder cancer identified
by Johannes Angerer, Medical University of Vienna Response of commercially available and patient-derived BC cell lines to varying concentrations of clofarabine. (A) Commercially available cell lines representing different intrinsic BC subtypes were treated with variable concentrations of clofarabine for 48 h. Apart from HT1367 and HT1197, all tested BC lines showed a concentration-dependent decrease of...
Study: Common virus may cause bladder cancer
by University of York Fig. 1: Schematic model of BKPyV hit-and-run carcinogenesis hypothesis. Immune-insufficiency leads to reactivation of latent BKPyV, sloughing of actively-infected renal “decoy” cells and BKPyV viruria. BKPyV infects the G0-arrested urothelium but remains episomal. In infected urothelial cells, BKPyV LT-Ag inhibits host retinoblastoma (pRb) and disables p53, releasing urothelial cells from G0...
Link between hypercholesterolemia and bladder cancer aggressiveness
by Liu Jia, Chinese Academy of Sciences Credit: Pixabay/CC0 Public Domain Hypercholesterolemia is a metabolic disorder commonly found in people with obesity. It has been reported as a risk factor in the development of the cancers derived from steroid-targeted tissues, such as breast and prostate cancer. However, little is known about the effects of hypercholesterolemia on...
Liquid biopsies may aid diagnosis, treatment of bladder, nerve tumors
by Julia Evangelou Strait, Washington University School of Medicine Credit: Pixabay/CC0 Public Domain Blood and urine tests could lead to faster and less invasive methods to diagnose and monitor various types of tumors, new research indicates. Two studies led by Washington University School of Medicine in St. Louis describe the potential of liquid biopsies to identify and track...
Experimental drug that boosts immunotherapy shows promise in bladder cancer study
by UNC Lineberger Comprehensive Cancer Center http://www.scientificanimations.com/, CC BY-SA 4.0 A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission. This approach shows such promise that it’s already being tested in an ongoing clinical trial in people with advanced bladder cancer. This finding, led by scientists...
New non-invasive test can detect bladder cancer
by Stony Brook University Microscopic image showing brown, antibody-based staining of keratin 17 (K17) in bladder cancer. Credit: Shroyer Lab, Stony Brook University A novel urine screening test that uses a protein, keratin 17 (K17), as a cancer biomarker reveals the test detects the presence of new or recurrent cases of bladder cancer. The methodology behind...
Oncotarget: Progression in high-risk non-muscle invasive bladder cancer
IMPACT JOURNALS LLC IMAGE: THE KAPLAN MEIER CURVE FOR PROGRESSION. CREDIT: CORRESPONDENCE TO – TAKASHI KAWAHARA – [email protected] Oncotarget published “A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer” which reported that a recent study revealed that a high De Ritis ratio was a risk factor in some...
Genes and immune cells predict immunotherapy success in bladder cancer
by The Mount Sinai Hospital Credit: CC0 Public Domain Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or...